Tribune Health, a Paris, France-based digital pathology company, raised €15M in Series B funding.
The round was led by Fonds Patient Autonome managed by Bpifrance, alongside new investors, including Owkin and Vivalto Family, and LBO France. Led by CEO Jean-François Pomerol, Tribun Health provides laboratories and pharmaceutical organizations with a computational platform that leverages AI technology for diagnosis, prognosis, and drug development. Its modular end-to-end platform empowers physicians to deliver personalized and timely therapies to patients and helps researchers to accelerate the development of new therapies. The funds will facilitate the expansion of sales and marketing activities in Europe and North America, bolster the development efforts, and scale up deployment resources to meet the growing demand for digital pathology solutions used in hospitals and private labs. It will additionally serve as funding for the recent purchase of Keen Eye company. The Keen Eye computational pathology platform, EyeDo, will be enhanced to capitalize on the secondary utilization of real-world oncology data for pharmaceutical and biotech purposes.11/09/2023
